Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 1-2/2009

01-06-2009 | REVIEW ARTICLE

Interplay of Tumor Microenvironment Cell Types with Parenchymal Cells in Pancreatic Cancer Development and Therapeutic Implications

Authors: Praveen Guturu, Vijay Shah, Raul Urrutia

Published in: Journal of Gastrointestinal Cancer | Issue 1-2/2009

Login to get access

Abstract

Introduction

The process of “induction,” namely, the formation of a tissue by the functional interaction between the epithelial layer and the stroma, is key for the development of many organs, in particular to the pancreas.

Discussion

In diseases like pancreatic cancer, most studies performed to date, in the area of pancreatic cancer, have focused on studying epithelial cells and their contribution to this disease. Strikingly, until recently, the stroma that surrounds cancer cells in pancreatic tumors (desmoplastic reaction–tumor microenvironment) has remained an underrepresented area of research. However, several laboratories are increasingly posing questions as what is the role of this tumor microenvironment in the development and progression of this fatal disease. Therefore, in the current article, we define and describe the components of this desmoplastic reaction and the pancreatic tumor microenvironment and briefly review advances being made. More importantly, we highlight the urgent need of research in this field.

Conclusion

We anticipate that, because of the paucity of knowledge on this subject, studies on the pancreatic tumor microenvironment will bring new concepts which will ultimately impact in designing new diagnosis and treatment for this disease.
Literature
2.
go back to reference Schneider G, Hamacher R, Eser S, Friess H, Schmid RM, Saur D. Molecular biology of pancreatic cancer—new aspects and targets. Anticancer Res. 2008;28:1541–50.PubMed Schneider G, Hamacher R, Eser S, Friess H, Schmid RM, Saur D. Molecular biology of pancreatic cancer—new aspects and targets. Anticancer Res. 2008;28:1541–50.PubMed
5.
6.
go back to reference Mulkeen AL, Yoo PS, Cha C. Less common neoplasms of the pancreas. World J Gastroenterol. 2006;12:3180–5.PubMed Mulkeen AL, Yoo PS, Cha C. Less common neoplasms of the pancreas. World J Gastroenterol. 2006;12:3180–5.PubMed
18.
go back to reference Clark CE, Beatty GL, Vonderheide RH. Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Lett. 2008;279:1–7.PubMedCrossRef Clark CE, Beatty GL, Vonderheide RH. Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Lett. 2008;279:1–7.PubMedCrossRef
19.
go back to reference Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, Perez-Gallego L, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell. 2007;11:291–302. doi:10.1016/j.ccr.2007.01.012.PubMedCrossRef Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, Perez-Gallego L, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell. 2007;11:291–302. doi:10.​1016/​j.​ccr.​2007.​01.​012.PubMedCrossRef
20.
go back to reference Monti P, Leone BE, Marchesi F, Balzano G, Zerbi A, Scaltrini F, et al. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res. 2003;63:7451–61.PubMed Monti P, Leone BE, Marchesi F, Balzano G, Zerbi A, Scaltrini F, et al. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res. 2003;63:7451–61.PubMed
21.
go back to reference Mytar B, Baj-Krzyworzeka M, Majka M, Stankiewicz D, Zembala M. Human monocytes both enhance and inhibit the growth of human pancreatic cancer in SCID mice. Anticancer Res. 2008;28:187–92.PubMed Mytar B, Baj-Krzyworzeka M, Majka M, Stankiewicz D, Zembala M. Human monocytes both enhance and inhibit the growth of human pancreatic cancer in SCID mice. Anticancer Res. 2008;28:187–92.PubMed
22.
go back to reference Esposito I, Menicagli M, Funel N, Bergmann F, Boggi U, Mosca F, et al. Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol. 2004;57:630–6. doi:10.1136/jcp. 2003.014498.PubMedCrossRef Esposito I, Menicagli M, Funel N, Bergmann F, Boggi U, Mosca F, et al. Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol. 2004;57:630–6. doi:10.​1136/​jcp.​ 2003.​014498.PubMedCrossRef
24.
go back to reference Calderon B, Suri A, Miller MJ, Unanue ER. Dendritic cells in islets of Langerhans constitutively present beta cell-derived peptides bound to their class II MHC molecules. Proc Natl Acad Sci U S A. 2008;105:6121–6. doi:10.1073/pnas.0801973105.PubMedCrossRef Calderon B, Suri A, Miller MJ, Unanue ER. Dendritic cells in islets of Langerhans constitutively present beta cell-derived peptides bound to their class II MHC molecules. Proc Natl Acad Sci U S A. 2008;105:6121–6. doi:10.​1073/​pnas.​0801973105.PubMedCrossRef
29.
go back to reference Zhu Z, Kleeff J, Kayed H, Wang L, Korc M, Buchler MW, et al. Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells. Mol Carcinog. 2002;35:138–47. doi:10.1002/mc.10083.PubMedCrossRef Zhu Z, Kleeff J, Kayed H, Wang L, Korc M, Buchler MW, et al. Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells. Mol Carcinog. 2002;35:138–47. doi:10.​1002/​mc.​10083.PubMedCrossRef
31.
go back to reference Ceyhan GO, Bergmann F, Kadihasanoglu M, Altintas B, Demir IE, Hinz U, et al. Pancreatic neuropathy and neuropathic pain—a comprehensive pathomorphological study of 546 cases. Gastroenterology. 2009;136:177.e1–86.e1.CrossRef Ceyhan GO, Bergmann F, Kadihasanoglu M, Altintas B, Demir IE, Hinz U, et al. Pancreatic neuropathy and neuropathic pain—a comprehensive pathomorphological study of 546 cases. Gastroenterology. 2009;136:177.e1–86.e1.CrossRef
33.
go back to reference Phillips PA, McCarroll JA, Park S, Wu MJ, Pirola R, Korsten M, et al. Rat pancreatic stellate cells secrete matrix metalloproteinases: implications for extracellular matrix turnover. Gut. 2003;52:275–82. doi:10.1136/gut.52.2.275.PubMedCrossRef Phillips PA, McCarroll JA, Park S, Wu MJ, Pirola R, Korsten M, et al. Rat pancreatic stellate cells secrete matrix metalloproteinases: implications for extracellular matrix turnover. Gut. 2003;52:275–82. doi:10.​1136/​gut.​52.​2.​275.PubMedCrossRef
36.
go back to reference Cartwright T, Richards DA, Boehm KA. Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network. Cancer Control. 2008;15:308–13.PubMed Cartwright T, Richards DA, Boehm KA. Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network. Cancer Control. 2008;15:308–13.PubMed
38.
go back to reference Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–6. doi:10.1200/JCO.2006.07.9525.PubMedCrossRef Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–6. doi:10.​1200/​JCO.​2006.​07.​9525.PubMedCrossRef
40.
go back to reference Gaspar NJ, Li L, Kapoun AM, Medicherla S, Reddy M, Li G, et al. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness. Mol Pharmacol. 2007;72:152–61. doi:10.1124/mol.106.029025.PubMedCrossRef Gaspar NJ, Li L, Kapoun AM, Medicherla S, Reddy M, Li G, et al. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness. Mol Pharmacol. 2007;72:152–61. doi:10.​1124/​mol.​106.​029025.PubMedCrossRef
41.
go back to reference Aikawa T, Gunn J, Spong SM, Klaus SJ, Korc M. Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther. 2006;5:1108–16. doi:10.1158/1535-7163.MCT-05-0516.PubMedCrossRef Aikawa T, Gunn J, Spong SM, Klaus SJ, Korc M. Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther. 2006;5:1108–16. doi:10.​1158/​1535-7163.​MCT-05-0516.PubMedCrossRef
43.
go back to reference Kindler H, Niedzwiecki D, Hollis D. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia. J Clin Oncol. 2007;25:4508. (abstract). Kindler H, Niedzwiecki D, Hollis D. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia. J Clin Oncol. 2007;25:4508. (abstract).
44.
go back to reference Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet. 2008;371:2101–8. doi:10.1016/S0140-6736(08)60661-3.PubMedCrossRef Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet. 2008;371:2101–8. doi:10.​1016/​S0140-6736(08)60661-3.PubMedCrossRef
Metadata
Title
Interplay of Tumor Microenvironment Cell Types with Parenchymal Cells in Pancreatic Cancer Development and Therapeutic Implications
Authors
Praveen Guturu
Vijay Shah
Raul Urrutia
Publication date
01-06-2009
Publisher
Humana Press Inc
Published in
Journal of Gastrointestinal Cancer / Issue 1-2/2009
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-009-9071-1

Other articles of this Issue 1-2/2009

Journal of Gastrointestinal Cancer 1-2/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.